



Dr. Emiliano Lepore
Co-founder and CEO



RECORNEA is a clinical stage medtech ophthalmic company developing therapeutic solutions for treating diseases of the eye.


We are raising an equity round of 1.2 M€ (750 k€ secured).

“ Preventing your blindness through innovation ”




A DEGENERATIVE EYE DISEASE ...

Normal
cornea




Keratoconus




Thinning and
protrusion of
the cornea

KERATOCONUS AFFECTS OVER 175M EYES WORLDWIDE



>175 M eyes affected globally
1.8 M new eyes/year



... THAT CAN SERIOUSLY AFFECT QUALITY OF LIFE



RECOVER VISION IN PATIENTS WITH KERATOCONUS



FIRST-EVER NITINOL CORNEAL IMPLANT TO TREAT KERATOCONUS



GROSSO[®]
implant


**GROSSO implant curvature is similar to
that of the physiological eye**

CAUTION: Investigational device. The GROSSO[®] device is for investigational use only, and not yet available for sale.

Note: for confidential reasons, the picture is not representative of the actual design of the GROSSO[®] Implant.

IN COMPETITION WITH ...

GROSSO[®]
implant



Intracorneal Ring Segments



>50% keratoconus cases
not solved,
potentially leading to
corneal transplant

RECORNEA **CAUTION:** Investigational device.
The GROSSO[®] device is for investigational use
only, and not yet available for sale.
securing your vision


ACHIEVEMENTS

- **COMPLETION OF THE PRE-CLINICAL TESTING**
- **ONGOING FIRST IN HUMAN CLINICAL STUDY IN SPAIN**
- **PATENTS GRANTED IN EU, US, JAPAN, EXTENDED IN 8**

COUNTRIES:




KERATOCONUS IS A LARGE MARKET ...




400 M€ X
15% market share
~**60 M€** by 2030

TREATMENT OPTIONS DIFFER ACCORDING TO STAGE




¹ INTACS by Avedro (US), FERRARA by AJL Ophthalmic (Spain), KERARING by Mediphacos(Brazil)

TREATMENT OPTIONS DIFFER ACCORDING TO STAGE



TREATMENT OPTIONS DIFFER ACCORDING TO STAGE



FOUNDERS



Emiliano Lepore

Co-founder, CEO, Board Member
+15ys exp

Business development / Product



Moses Kakanga

Co-founder, CSO, Board Member
+15ys exp

Clinical trials / Quality mgt system




Edoardo Grosso, MD

Co-founder, Eye surgeon
+15ys exp

Clinical Advisor / Product Innovation

TEAM



... A TOP-LEVEL ADVISORY BOARD

BUSINESS



SIVARAM RAJAGOPALAN 30+yrs exp.
in MedTech industry across Asia Pacific
Advisor – Business Development



Laerdal
helping save lives



CLINICAL



Prof. JOSE GÜELL

Head of Cornea, Cataract and
Refractive Surgery Department of
IMO



Prof. FRANÇOIS MALECAZE

Head of the ophthalmology
department of the Toulouse University
Hospital

RAISING ENTHUSIASTIC RESPONSE IN THE MARKET

22+

Key Opinion leaders already engaged in the project

10+

LOIs signed by hospitals and clinics

5

LOIs signed by ophthalmology companies and distributors



GO-TO-MARKET STRATEGY



RECORNEA
securing your vision

RECORNEA
securing your vision

Partners
certified
ISO 13485

Int'l
distributors

Hospital/
clinics



40-50€


350-500€

600-1,000€

RECORNEA
securing your vision

ROADMAP AND MILESTONES

 = pre-clinical phase
 = clinical phase



FUNDS SECURED TILL NOW

NON-DILUTIVE:

€1.7 M



EUROPEAN COMMISSION



ITALIAN GOVERNMENT

DILUTIVE:

€200 K



ENTREPRENEUR FIRST, UK/SINGAPORE



GFACTOR, ITALY



HEALTH WILDCATTERS, US

CURRENT ASK

OPEN **SEED** ROUND:

€1.2 M

SECURED - €750 K

SEARCHING: €450 K

USE OF FUNDS:

- CLINICAL: FIH STUDY (12 PATIENTS) – 2024/2025

NEXT: €7-10 M SERIES A FOR PIVOTAL TRIAL, REIMBURSEMENT, CE/FDA MARK

PIPELINE OF OUR PROPRIETARY TECHNOLOGY



GROSSO IMPLANT
FOR KERATOCONUS



**SCAFFOLD SUPPORTED
STEM CELL-BASED
ARTIFICIAL CORNEA**
FOR CORNEAL TRANSPLANTS



IMPLANTABLE FILTERING DEVICE
FOR GLAUCOMA



2019



TOP5% MOST
INNOVATIVE
COMPANIES IN EU

2023



TOP FINALIST,
AUSTRIA

RECORNEA

Preventing blindness through innovation



Emiliano Lepore,
CEO



el@recornea.com



Moses Kakanga,
CSO



km@recornea.com



www.recornea.com

